Services For
News & Updates
Sanofi Pasteur and International Vaccine Institute Partner against Dengue
ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin
India's Drug Technical Advisory Board (DTAB) has decided to ban two controversial drugs - Gatifloxacine and Tegaserod - because of their side-effects
MoH bans nimesulide suspension, cisapride, phenylpropanolamine, human placenta extracts, Sibutramine and R-Sibutramine

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Welcome to Ossinc

Our years of experiences and expertise have made us renowned and reliable Service providers to clinical research industry. "When you work as organized team, then best results are obtained ".

Following this, we always go a step further to become our clients' ultimate partner in their study, to precisely understand their requirements and provide optimal solutions.

We use our extensive experience along with the appropriate approach for working in INDIA in order to achieve resultsthat exceed the expectations.Our professional expertise covers advisory activities, planning and analysis of clinical trials.

Choose Us Because
Contact Us

INDIA:
OSSINC INDIA(OSSINC)
A 48 Raja JI Puram
Lucknow 226017
Uttar Pradesh
Phone: +91-9838172269
            +91-7379737763
            +91-09369311922
Fax: +91-522-4012214
LL: +91-522-4012212
Email: bd@ossinc.org , contact@ossinc.org

U.S.A:
OSS Research International INC.,
5348, Vegas Dr., Las Vegas,
NV 891082347,
U.S.A.
Email: info@ossresearchinternational.com
Potential Recruiters